新冠肺炎奥密克戎变异株中成药应用专家共识

Expert Consensus on Application of Chinese Patent Medicine of COVID-19 Omicron Mutant

新冠肺炎自2020年爆发以来,中医药取得举世瞩目的救治效果,在全球疫情防控中发挥着重要作用,获得了WHO的高度肯定。2021年11月新冠肺炎奥密克戎(Omicron)变异株首次出现并迅速传播,我国吉林、上海先后出现爆发并蔓延全国。为了更加有效应对奥密克戎变异株感染,世界中医药学会联合会急症专业委员会、中华医学会急诊分会中西医结合急救学组、中国医师协会急诊医师分会中西医结合急救医学学组、上海中医药学会急诊分会、上海中医药大学急危重研究所等学术机构组织奥密克戎新冠肺炎变异株一线救治专家,根据上海、吉林等奥密克戎感染地区患者中医临床症候,并结合国家《新型冠状病毒诊疗方案(试行第九版)》,就中成药应用相关问题展开调研与讨论,形成本共识,以期对当下新冠肺炎奥密克戎变异株感染乃至以后疫情防控起到临床指导作用。

Since the outbreak of COVID-19 in 2020,Chinese medicine has achieved remarkable treatment results,played an important role in the global epidemic prevention and control,and was highly recognized by WHO.In November 2021,the COVID-19 Omicron mutant appeared for the first time and spread rapidly.Jilin and Shanghai in China successively broke out and spread throughout the country.In order to more effectively respond to the infection of Omikron’s variant strain,the World Federation of Chinese Medical Societies Emergency Committee,the First Aid Group of Integrated Traditional Chinese and Western Medicine of the Emergency Branch of the Chinese Medical Association,the First Aid Group of Integrated Traditional Chinese and Western Medicine of the Emergency Branch of the Emergency Physician Branch of the Chinese Medical Association,the Emergency Branch of the Shanghai Chinese Medical Association,the Institute of Emergency and Critical Care of the Shanghai University of Traditional Chinese Medicine and other academic institutions have organized first-line treatment experts for Omikron’s COVID-19 variant strain.The clinical symptoms of patients in Jilin and other areas infected with Omikron were investigated and discussed on issues related to the application of Chinese patent medicine in combination with the National Diagnosis and Treatment Plan forCOVID-19(Trial Version 9),and a consensus was formed,with a view to playing a clinical guiding role in the prevention and control of the current infection of Omikron variant of COVID-19 and the future epidemic situation.